Gene editing with adeno‐associated virus (AAV) delivery of CRISPR–Cas9 has been efficacious in mice, where removal of the early termination codon of dystrophin in the DMD model has shown partial correction of dystrophin expression, rescuing phenotype in cardiac and skeletal muscle (Long et al., 2016). This evidence concerns the gene DMD and Duchenne muscular dystrophy.